Evidence map›Paper›PMID 29222253›Full record

ReviewHematology. American Society of Hematology. Education Program2017

New monogenic disorders identify more pathways to neutropenia: from the clinic to next-generation sequencing.

Seth J Corey, Usua Oyarbide

Open access · bronzeAbstract readReview
In one paragraph

Review in Hematology. American Society of Hematology. Education Program, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Seth J CoreyDepartment of Pediatrics, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA.
Usua OyarbideDepartment of Pediatrics, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA.
Virginia Commonwealth University · US

Funding

Multiscale Modeling of Myelodysplastic SyndromesR01HL128173 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI COREY, SETH JOEL, KIMMEL, MAREK · 2015 to 2019
$3.8M
Genetic Modifiers for Cancer Stem Cells in Secondary MDS/AMLR21CA159203 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI COREY, SETH JOEL · 2014 to 2015
$374k
NCI NIH HHS R21 CA159203NHLBI NIH HHS R01 HL128173
6 · The paper itself

Abstract

Neutrophils are the most common type of leukocyte in human circulating blood and constitute one of the chief mediators for innate immunity. Defined as a reduction from a normal distribution of values, neutropenia results from a number of congenital and acquired conditions. Neutropenia may be insignificant, temporary, or associated with a chronic condition with or without a vulnerability to life-threatening infections. As an inherited bone marrow failure syndrome, neutropenia may be associated with transformation to myeloid malignancy. Recognition of an inherited bone marrow failure syndrome may be delayed into adulthood. The list of monogenic neutropenia disorders is growing, heterogeneous, and bewildering. Furthermore, greater knowledge of immune-mediated and drug-related causes makes the diagnosis and management of neutropenia challenging. Recognition of syndromic presentations and especially the introduction of next-generation sequencing are improving the accuracy and expediency of diagnosis as well as their clinical management. Furthermore, identification of monogenic neutropenia disorders is shedding light on the molecular mechanisms of granulopoiesis and myeloid malignancies.

Indexed as

Genetic Diseases, InbornHigh-Throughput Nucleotide SequencingNeutropeniaHumans

Identifiers

PMID29222253
PMCPMC5912212
OpenAlexW2785706014

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.